Author:
Wong Muh Geot,Perkovic Vlado,Chalmers John,Woodward Mark,Li Qiang,Cooper Mark E.,Hamet Pavel,Harrap Stephen,Heller Simon,MacMahon Stephen,Mancia Giuseppe,Marre Michel,Matthews David,Neal Bruce,Poulter Neil,Rodgers Anthony,Williams Bryan,Zoungas Sophia
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference21 articles.
1. U.S. Renal Data System. USRDS 2014 Annual Data Report: Cost of End-stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Insitute of Diabetes and Digestive and Kidney Diseases, 2014
2. Worldwide access to treatment for end-stage kidney disease: a systematic review
3. Australian Institute of Health and Welfare. Cardiovascular Disease, Diabetes and Chronic Kidney Disease—Australian Facts: Prevalence and Incidence. no. 2. Cat. no. CDK 2. Canberra, Australia, Australian Institute of Health and Welfare, 2014
4. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
5. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy